BRPI0418231A - compostos de pirrolotriazina como inibidores da cinase - Google Patents

compostos de pirrolotriazina como inibidores da cinase

Info

Publication number
BRPI0418231A
BRPI0418231A BRPI0418231-6A BRPI0418231A BRPI0418231A BR PI0418231 A BRPI0418231 A BR PI0418231A BR PI0418231 A BRPI0418231 A BR PI0418231A BR PI0418231 A BRPI0418231 A BR PI0418231A
Authority
BR
Brazil
Prior art keywords
compounds
formula
kinase inhibitors
useful
growth factor
Prior art date
Application number
BRPI0418231-6A
Other languages
English (en)
Inventor
Brian E Fink
Ashvinikumar V Gavai
Gregory D Vite
Ping Chen
Harold Mastalerz
Derek J Norris
John S Tokarski
Yufen Zhao
Wen-Ching Han
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0418231A publication Critical patent/BRPI0418231A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"COMPOSTOS DE PIRROLOTRIAZINA COMO INIBIDORES DA CINASE". A presente invenção proporciona compostos de fórmula (I); e seus sais farmaceuticamente aceitáveis. Os compostos de fórmula (I) inibem a atividade de tirosina cinase dos receptores dos fatores do crescimento, tais como o HER1, o HER2 e o HER4, desse modo os tornando úteis como agentes antiproliferativos. Os compostos de fórmula (I) também são úteis para o tratamento de outras doenças associadas com as vias de transdução de sinais que operam através dos receptores dos fatores do crescimento.
BRPI0418231-6A 2003-12-29 2004-12-23 compostos de pirrolotriazina como inibidores da cinase BRPI0418231A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53333503P 2003-12-29 2003-12-29
PCT/US2004/043169 WO2005066176A1 (en) 2003-12-29 2004-12-23 Pyrrolotriazine compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0418231A true BRPI0418231A (pt) 2007-04-27

Family

ID=34748887

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418231-6A BRPI0418231A (pt) 2003-12-29 2004-12-23 compostos de pirrolotriazina como inibidores da cinase

Country Status (32)

Country Link
US (4) US7141571B2 (pt)
EP (2) EP1699797B1 (pt)
JP (1) JP4740878B2 (pt)
KR (1) KR100839716B1 (pt)
CN (1) CN1922182B (pt)
AR (1) AR047076A1 (pt)
AT (1) ATE443706T1 (pt)
AU (1) AU2004312413C1 (pt)
BR (1) BRPI0418231A (pt)
CA (1) CA2552107C (pt)
CL (1) CL2009001492A1 (pt)
CY (1) CY1109662T1 (pt)
DE (1) DE602004023324D1 (pt)
DK (1) DK1699797T3 (pt)
ES (1) ES2331842T3 (pt)
GE (1) GEP20105081B (pt)
HK (1) HK1088332A1 (pt)
HR (1) HRP20090601T1 (pt)
IL (1) IL176450A0 (pt)
MX (1) MXPA06007038A (pt)
MY (1) MY145634A (pt)
NO (1) NO20062763L (pt)
NZ (2) NZ573544A (pt)
PE (1) PE20050679A1 (pt)
PL (1) PL1699797T3 (pt)
PT (1) PT1699797E (pt)
RU (1) RU2373209C2 (pt)
SI (1) SI1699797T1 (pt)
TW (1) TWI332840B (pt)
UA (1) UA89038C2 (pt)
WO (1) WO2005066176A1 (pt)
ZA (1) ZA200605160B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
DK1497019T3 (en) * 2002-04-23 2015-08-03 Bristol Myers Squibb Co PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
WO2006104971A1 (en) 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CN101448506A (zh) * 2005-12-02 2009-06-03 拜尔健康护理有限责任公司 通过抑制有丝分裂酶激酶治疗癌症的吡咯并三嗪衍生物
US8063208B2 (en) * 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
WO2008057863A1 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
US7820421B2 (en) 2007-02-08 2010-10-26 Codexis, Inc. Ketoreductases and uses thereof
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
EP2231662B1 (en) * 2007-12-19 2011-06-22 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
WO2010042684A1 (en) * 2008-10-08 2010-04-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
AU2010206161B2 (en) 2009-01-21 2014-08-07 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
JPWO2011013656A1 (ja) * 2009-07-28 2013-01-07 宇部興産株式会社 ピロロ［２，３−ｄ］ピリミジン誘導体
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
PL2589592T3 (pl) 2010-06-30 2019-03-29 Fujifilm Corporation Nowe pochodne nikotynamidu lub ich sole
CN102153558B (zh) * 2011-02-23 2012-11-21 扬州永济医药新技术有限公司 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
NZ722019A (en) * 2014-01-13 2022-07-01 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
JP6279104B2 (ja) * 2014-05-12 2018-02-14 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド 質量分析によるタモキシフェンおよびその代謝産物の定量化
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用
US20240132521A1 (en) * 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
CN1227554A (zh) 1996-08-28 1999-09-01 辉瑞大药厂 取代的6,5－杂二环衍生物
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
MXPA01011832A (es) 1999-05-21 2002-06-21 Squibb Bristol Myers Co Inhibidores de cinasas, de pirrolotriazina.
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
JP2004522713A (ja) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
DK1497019T3 (en) 2002-04-23 2015-08-03 Bristol Myers Squibb Co PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS
EP1503996B1 (en) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US6894066B2 (en) 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
US6951859B2 (en) 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
JP4740878B2 (ja) 2011-08-03
DK1699797T3 (da) 2010-01-04
EP1699797A1 (en) 2006-09-13
KR100839716B1 (ko) 2008-06-19
CA2552107A1 (en) 2005-07-21
AU2004312413B2 (en) 2010-07-22
ES2331842T3 (es) 2010-01-18
SI1699797T1 (sl) 2010-04-30
RU2373209C2 (ru) 2009-11-20
GEP20105081B (en) 2010-09-27
HRP20090601T1 (hr) 2009-12-31
TW200526226A (en) 2005-08-16
US20060264438A1 (en) 2006-11-23
MY145634A (en) 2012-03-15
US20110039838A1 (en) 2011-02-17
US7846931B2 (en) 2010-12-07
US20050182058A1 (en) 2005-08-18
AR047076A1 (es) 2006-01-04
PE20050679A1 (es) 2005-09-25
UA89038C2 (en) 2009-12-25
WO2005066176A1 (en) 2005-07-21
RU2006127396A (ru) 2008-02-10
ZA200605160B (en) 2007-12-27
MXPA06007038A (es) 2006-08-31
NZ548070A (en) 2009-02-28
DE602004023324D1 (de) 2009-11-05
NO20062763L (no) 2006-09-11
CY1109662T1 (el) 2014-08-13
TWI332840B (en) 2010-11-11
PT1699797E (pt) 2009-12-29
AU2004312413C1 (en) 2011-01-27
US7297695B2 (en) 2007-11-20
EP2058314A1 (en) 2009-05-13
CN1922182B (zh) 2010-08-18
PL1699797T3 (pl) 2010-02-26
AU2004312413A1 (en) 2005-07-21
EP1699797B1 (en) 2009-09-23
US7141571B2 (en) 2006-11-28
NZ573544A (en) 2010-04-30
KR20060107828A (ko) 2006-10-16
JP2007518721A (ja) 2007-07-12
IL176450A0 (en) 2006-10-05
CA2552107C (en) 2011-10-18
CL2009001492A1 (es) 2010-01-15
CN1922182A (zh) 2007-02-28
ATE443706T1 (de) 2009-10-15
HK1088332A1 (en) 2006-11-03
US20090048244A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
BR0316755A (pt) Indazolilpirrolotriazinas modificadas por c-6
BR0214112A (pt) Indazolilpirrolotriazinas modificadas c-5
BR0312801A (pt) inibidores de azaindol cinase
ATE482212T1 (de) Pyrrolotriazinverbindungen
BR0010482A (pt) Inibidores pirrolotriazìnicos de cinases
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
BR0208373A (pt) Inibidores da tirosina cinase
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BR0312464A (pt) Inibidores de tirosina quinases
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BR9910792A (pt) Inibidores de quinase protéica 2-indolinona substituìda com pirrol
BRPI0414489A8 (pt) derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
BRPI0517921A (pt) métodos para preparar compostos de indazol
TR200102782T2 (tr) Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar
BR0313297A (pt) 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
BR0208353A (pt) Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças
BRPI0607432A2 (pt) derivado de quinazolina ou um sal farmacêuticamente aceitável do mesmo, composto, composição farmacêutica, uso de um derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo
BRPI0409505A (pt) compostos como antagonistas do receptor crf1
ATE421510T1 (de) Kompetitive atp-kinasehemmer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.